论文部分内容阅读
Takeda公司的帕秦克隆（pazinaclone，DN－2327）是一种苯并二氮章受体激动剂，在德国的一项为期4周的D期临床研究中，本品能使焦虑症病人的几项指标有明显的改善。在这一研究中，126例门诊广泛性焦虑症病人随机接受安慰剂或本品4mg，一日2次，用药4周。与基线值及安慰剂组相比
Takeda’s pazinaclone (DN-2327) is a benzodiazepine receptor agonist. In a 4-week phase D clinical study in Germany, this product enabled patients with anxiety disorders Indicators have significantly improved. In this study, 126 outpatients with generalized anxiety disorder were randomized to receive either placebo or 4 mg twice daily for 4 weeks. Compared with baseline and placebo group